Targeting PCSK9:a promising adjuvant strategy in cancer immunotherapy

作     者：Catarina R.Almeida Beatriz H.Ferreira lola F.Duarte Catarina R.Almeida;Beatriz H.Ferreira;Iola F.Duarte

作者机构：iBiMED-Institute of BiomedicineDepartment of Medical SciencesUniversity of AveiroAveiroPortugal CICECO-Aveiro Institute of MaterialsDepartment of ChemistryUniversity of AveiroAveiroPortugal 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2021年第6卷第4期

页      面：1081-1083页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported, respectively, by iBiMED - Institute of Biomedicine CICECO - Aveiro Institute of Materials financed by national funds through the Foundation for Science and Technology (FCT/MCTES. B.H.F. is supported by FCT through an individual grant) 

主　　题：al. prognosis adjuvant 

摘      要：Treatment with immune checkpoint inhibitors(ICIs)has drastically improved the prognosis of certain advanced-stage ***,low response rates and the development of resistance remain important *** a study recently published in Nature,Li et *** that antibody inhibitors of proprotein convertase subtilisin/kexin type 9(PCSK9),FDA-approved for hyperlipidemia treatment,have the potential to boost the anticancer efficacy of ICIs.